Sun Pharma To Foray Into Large European Markets To Sell Hospital Products
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Sun Pharmaceutical - the most highly valued Indian drug company - is soon establishing its direct presence in Europe. The move comes years after Sun Pharma's top Indian rivals Ranbaxy, Dr. Reddy's and Wockhardt set up their operations in Europe through organic route or by acquiring established generic drug businesses
You may also be interested in...
Taro’s Merger Proposal At $15 A Share “Outrageous,” Sun Says; Extends Offer Deadline
MUMBAI - The war of words between Sun Pharmaceutical and Israeli drug maker Taro has intensified as the two companies exchange proposals and counter-proposals for a merger as directed by Israel's Supreme Court
Sun Pharma Buys Chattem Chemicals To Augment Its Controlled Substances Business
MUMBAI - The global economic downturn is throwing up acquisition possibilities for Indian pharmaceutical companies. India's Sun Pharma has lapped up U.S. based Chattem Chemicals, a registered narcotic API importer and producer based in Chattanooga, Tenn., for an undisclosed amount
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).